Progress on new Indian regulatory system
This article was originally published in Clinica
The Indian government is in the process of considering the type of regulatory system it will put in place for medical technology. Companies supplying medical technology in India have been concerned that the government might adopt a regulatory system that would be burdensome, detailed, complex and not appropriate for medical technology.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.